Novo Nordisk

Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade

The company is still 'evaluating' the price of the drug, but is confident that the price-sensitive Indian population will be able to afford it, Novo's India Managing Director Vikrant Shrotriya said

The Danish company lowered its forecast for operating profit growth this year to between 20% and 28% in local currencies, compared to its previous forecast of 22% to 30%

The company announced the plan to hire about 1,300 new employees by the end of 2026, as per the statement at a media briefing

The sales of Novo Nordisk's Rybelsus tablet, used for diabetes treatment and weight reduction, more than doubled to Rs 363 crore this year from Rs 147 crore last year

For Novo Holdings, which invests in life science companies and had assets of 108 billion euros ($115.86 billion) at end-2022, its recent investment in India was its largest in Asia to date

Novo Holdings' key markets in the region are India, South-East Asia and China, where it opened an office in Shanghai last year

Novo's biggest shareholder is buying Catalent Inc., one of the world's biggest drug-manufacturing companies, for $16.5 billion, including debt. In a three-way arrangement

State and local governments across the US are grappling with a growing problem: Expensive drugs to treat diabetes and obesity are threatening to drain their health-care budgets

IndiaMART, one of India's top online marketplaces, allows dealers to sell on its website after a nominal background check and says it has minimal control over what is advertised and sold

He urged patients not to buy copycat versions of Wegovy, warning they could be unsafe

Wegovy, a weekly injection, is the most effective treatment approved for weight-loss to date at a time when global obesity rates are at a record high

The company's share price closed up 0.7 per cent to DKK 1,311 ($190), giving the company a market capitalisation of $428 billion

Another patient on Saxenda, Novo's earlier and less effective weight-loss drug that contains a different active ingredient, reported thoughts of self-injury, the agency said

The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials

Plans to bring new drugs by 2025 into the country, which is part of all its global clinical trials

IT services company HCL Technologies on Monday said it has been selected to provide global service desk and on-site support to global healthcare company Novo Nordisk

He returns to India after 13 years with an overall career spanning over 20 years in the healthcare industry in India and internationally

Around 6.98 million insulin pens were sold; it was 6.97 mn in the year-before period

Novo Nordisk premium will survive drug wars